{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-23-000119","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.250514+00:00","generated_at":"2026-06-14T13:10:24.979695+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zentalis announces positive Phase 1b data for azenosertib; plans Phase 3 trial in Cyclin E1+ ovarian cancer","bullets":["Azenosertib + paclitaxel achieved 50% ORR (7.4 months mPFS) in platinum-resistant ovarian cancer.","Cyclin E1+ tumors showed 40% ORR vs 8.3% in Cyclin E1- (HR=0.37; p=0.0078).","Well tolerated; Grade ≥3 AEs: thrombocytopenia (27.5%), neutropenia (25.5%), anemia (15.7%), fatigue (9.8%).","Phase 3 study of azenosertib in combination with chemotherapy in Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-23-000119","json":"https://secwatch.observer/filing/0001725160-23-000119.json","markdown":"https://secwatch.observer/filing/0001725160-23-000119.md","text":"https://secwatch.observer/filing/0001725160-23-000119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000119/0001725160-23-000119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000119/zntl-20230525.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T13:10:24.979695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}